Loading…
Loading…
LVTTF (Levitee Labs Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
LVTTF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LVTTF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LVTTF and 80,000+ other tickers.
See exactly how LVTTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LVTTF and 80,000+ other tickers.
Levitee Labs Inc. is a holistic wellness enterprise dedicated to providing advanced, evidence-backed alternative treatments, including innovative psychedelic therapies. The company's operations are structured into two primary divisions: Medical Services and Product Sales. Through these, Levitee Labs delivers a range of treatments and medications addressing a broad spectrum of conditions such as substance addiction, various forms of chronic pain (including myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome), hepatitis-C, and mental health challenges. Its physical…
Toronto, Ontario--(Newsfile Corp. - Le 26 janvier/January 2026) - The common shares of Levitee Labs Inc. will be delisted from the CSE at market close today, January 26, 2026. Levitee Labs Inc. is currently suspended.
Levitee Labs (CSE:LVT) Inc has announced the completion of the sale of the right, title and interest in all of the assets of Earth Circle Organics Chain Inc to B&W Acquisition Corp on August 29, 2022. Under the terms of the asset purchase agreement, dated July 22, 2022, the purchaser had agreed to acquire the Earth Circle assets via a cash payment of US$329,950; deferred cash payment of $100,000 to be released at a future date following the closing; a credit for assumed liabilities paid at the closing; and the forgiveness of all unpaid prior debts owed by the company.
Levitee Labs (CSE:LVT) Inc has appointed economist David Bentil as chief executive officer and director following the resignation of Philip van den Berg as interim CEO and director. The integrative wellness company said Bentil is the founder of a private business with revenues ranging from $19 million to $25 million annually, and has been a director in multiple publicly-traded companies.
Levitee Labs (CSE:LVT) Inc announced the appointment of Philip van den Berg as the company's new interim CEO and director, effectively immediately, replacing Pouya Farmand who will be moving to the position of founder. Levitee said Farmand will continue to work with the company on key business development initiatives and help transition the leadership, but will be stepping down from the board of directors of Levitee Labs (CSE:LVT).
Levitee Labs (CSE:LVT) Inc, a wellness company with an established portfolio of cash-flowing wellness assets, has revealed that it is proposing to complete a non-brokered private placement of up to 15 million units at a price of C$0.20 each for aggregate gross proceeds of up to C$3 million. The Vancouver, British Columbia-based company said the proceeds will be used for “organic and inorganic growth initiatives” and to refocus the company on clinical healthcare with an emphasis on addiction services.